m6A结合蛋白LRPPRC促进多发性骨髓瘤的肿瘤发生
The m6A-Binding Protein LRPPRC Promotes the Tumorigenesis of Multiple Myeloma
DOI: 10.12677/acm.2025.1561709, PDF,    科研立项经费支持
作者: 唐嘉欣:青岛大学青岛医学院,山东 青岛;覃诗雨, 肖 瑜, 刘佳欣, 陈 娴*, 张昀源*:青岛大学青岛医学院,山东 青岛;青岛大学附属医院检验科,山东 青岛
关键词: LRPPRC多发性骨髓瘤m6A生物信息学分析预后LRPPRC Multiple Myeloma m6A Bioinformatics Analysis Prognosis
摘要: 目的:探讨N6-甲基腺苷(N6-methyladenosine, m6A)结合蛋白富含亮氨酸的五肽重复蛋白(leucine-rich pentatricopeptide repeat-containing, LRPPRC)在多发性骨髓瘤(multiple myeloma, MM)中的临床意义及生物学功能。方法:采用生物信息学方法筛选MM中差异表达的m6A相关蛋白,qRT-PCR检测LRPPRC在MM患者骨髓样本中的表达水平,并通过qRT-PCR和western blot检测其在MM细胞系中的表达。通过体外实验CCK-8实验、细胞周期分析和凋亡实验评估LRPPRC对MM进展的影响。结果:多个数据库筛选出LRPPRC是MM中关键的差异表达m6A基因,其表达在MM患者中显著升高,并与MM分期及较差的预后密切相关。在U266、RPMI-8226和MM.1S三种MM细胞系及患者骨髓样本中证实LRPPRC高表达。此外,LRPPRC表达与ISS分期呈正相关。敲低LRPPRC可抑制MM细胞增殖,促进凋亡并诱导细胞周期阻滞。结论:本研究表明,LRPPRC可能成为MM潜在的预后标志物和治疗靶点。
Abstract: Objectives: To explore the clinical relevance and biological roles of the N6-methyladenosine (m6A) binding protein leucine-rich pentatricopeptide repeat-containing protein (LRPPRC) in multiple myeloma (MM), aiming to offer new insights into its potential as a prognostic marker and therapeutic target for MM. Methods: Bioinformatics methodologies were employed to identify m6A-associated proteins exhibiting differential expression in MM. The expression levels of LRPPRC in the bone marrow of MM patients were assessed using Quantitative Real-Time PCR (qRT-PCR). Additionally, the expression of LRPPRC in MM cell lines was evaluated through qRT-PCR and Western blot analysis. In vitro experiments, including CCK-8 assays, cell cycle analyses, and apoptosis assays, were conducted to assess the impact of LRPPRC on MM progression. Results: We identified LRPPRC as a critical m6A differentially expressed gene in MM, observing that its expression was significantly upregulated in MM. This upregulation was positively correlated with the staging of MM and associated with poorer prognoses in MM patients. Furthermore, we confirmed elevated LRPPRC expression in three MM cell lines U266, RPMI-8226, and MM.1S as well as in the bone marrow of MM patients. Additionally, LRPPRC expression demonstrated a positive correlation with the International Staging System (ISS) stages of MM. Furthermore, LRPPRC knockdown inhibited the proliferation of MM cells, enhanced apoptosis, and induced cell cycle arrest. Conclusion: The study suggests that LRPPRC may serve as a potential prognostic target for MM.
文章引用:唐嘉欣, 覃诗雨, 肖瑜, 刘佳欣, 陈娴, 张昀源. m6A结合蛋白LRPPRC促进多发性骨髓瘤的肿瘤发生[J]. 临床医学进展, 2025, 15(6): 136-147. https://doi.org/10.12677/acm.2025.1561709

参考文献

[1] Malard, F., Neri, P., Bahlis, N.J., Terpos, E., Moukalled, N., Hungria, V.T.M., et al. (2024) Multiple Myeloma. Nature Reviews Disease Primers, 10, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
[2] Saghchy Khorasani, A.B., Soufizomorrod, M. and Bashash, D. (2024) Unleashing the Impact of Exosomes Derived from Human Placental Mesenchymal Stem Cells (hPMSCs) on U-266 Myeloma Cell Line. International Journal of Hematology-Oncology and Stem Cell Research, 18, 274-284. [Google Scholar] [CrossRef] [PubMed]
[3] Rafae, A., van Rhee, F. and Al Hadidi, S. (2023) Perspectives on the Treatment of Multiple Myeloma. The Oncologist, 29, 200-212. [Google Scholar] [CrossRef] [PubMed]
[4] Zhuang, H., Yu, B., Tao, D., Xu, X., Xu, Y., Wang, J., et al. (2023) The Role of m6A Methylation in Therapy Resistance in Cancer. Molecular Cancer, 22, Article No. 91. [Google Scholar] [CrossRef] [PubMed]
[5] Cui, J., Wang, L., Ren, X., Zhang, Y. and Zhang, H. (2019) LRPPRC: A Multifunctional Protein Involved in Energy Metabolism and Human Disease. Frontiers in Physiology, 10, Article 595. [Google Scholar] [CrossRef] [PubMed]
[6] Singh, V., Moran, J.C., Itoh, Y., Soto, I.C., Fontanesi, F., Couvillion, M., et al. (2024) Structural Basis of LRPPRC-SLIRP-Dependent Translation by the Mitoribosome. Nature Structural & Molecular Biology, 31, 1838-1847. [Google Scholar] [CrossRef] [PubMed]
[7] Ge, Y., Janson, V. and Liu, H. (2024) Comprehensive Review on Leucine-Rich Pentatricopeptide Repeat-Containing Protein (LRPPRC, PPR Protein): A Burgeoning Target for Cancer Therapy. International Journal of Biological Macromolecules, 282, Article ID: 136820. [Google Scholar] [CrossRef] [PubMed]
[8] Wu, Z., Liu, X., Xie, F., Ma, C., Lam, E.W., Kang, N., et al. (2024) Comprehensive Pan-Cancer Analysis Identifies the RNA-Binding Protein LRPPRC as a Novel Prognostic and Immune Biomarker. Life Sciences, 343, Article ID: 122527. [Google Scholar] [CrossRef] [PubMed]
[9] Wang, H., Tang, A., Cui, Y., Gong, H. and Li, H. (2023) LRPPRC Facilitates Tumor Progression and Immune Evasion through Upregulation of m6A Modification of PD-L1 mRNA in Hepatocellular Carcinoma. Frontiers in Immunology, 14, Article 1144774. [Google Scholar] [CrossRef] [PubMed]
[10] Sun, Y., Chen, X., Shi, Y., Teng, F., Dai, C., Ge, L., et al. (2024) Hsa_circ_0020093 Suppresses Ovarian Cancer Progression by Modulating LRPPRC Activity and miR-107/LATS2 Signaling. Biology Direct, 19, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, X., Yang, Y., Tian, Z., et al. (2025) Programmable Loading of a Multivalent LRPPRC Aptamer onto a Rectangular DNA Tile Inhibits the Proliferation of Lung Adenocarcinoma Cells. ACS Applied Materials & Interfaces, 17, 23722-23730. [Google Scholar] [CrossRef] [PubMed]
[12] Deng, L., Deng, W., Fan, S., Chen, M., Qi, M., Lyu, W., et al. (2022) m6A Modification: Recent Advances, Anticancer Targeted Drug Discovery and Beyond. Molecular Cancer, 21, Article No. 52. [Google Scholar] [CrossRef] [PubMed]
[13] Wei, G. (2024) RNA m6A Modification, Signals for Degradation or Stabilisation? Biochemical Society Transactions, 52, 707-717. [Google Scholar] [CrossRef] [PubMed]
[14] Qiao, Y., Sun, Q., Chen, X., He, L., Wang, D., Su, R., et al. (2023) Nuclear m6A Reader YTHDC1 Promotes Muscle Stem Cell Activation/Proliferation by Regulating mRNA Splicing and Nuclear Export. eLife, 12, e82703. [Google Scholar] [CrossRef] [PubMed]
[15] Zhang, X., Su, T., Wu, Y., Cai, Y., Wang, L., Liang, C., et al. (2024) N6-Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression. Cancer Research, 84, 827-840. [Google Scholar] [CrossRef] [PubMed]
[16] Chen, J., Lu, T., Wang, T., Yan, W., Zhong, F., Qu, X., et al. (2024) The m6A Reader HNRNPC Promotes Glioma Progression by Enhancing the Stability of IRAK1 mRNA through the MAPK Pathway. Cell Death & Disease, 15, Article No. 390. [Google Scholar] [CrossRef] [PubMed]
[17] Zhou, W., Lu, Q., Li, Q., Wang, L., Ding, S., Zhang, A., et al. (2017) PPR-SMR Protein SOT1 Has RNA Endonuclease Activity. Proceedings of the National Academy of Sciences of the United States of America, 114, E1554-E1563. [Google Scholar] [CrossRef] [PubMed]
[18] McDowell, R., Small, I. and Bond, C.S. (2022) Synthetic PPR Proteins as Tools for Sequence-Specific Targeting of RNA. Methods, 208, 19-26. [Google Scholar] [CrossRef] [PubMed]
[19] Weißenberger, S., Soll, J. and Carrie, C. (2016) The PPR Protein SLOW GROWTH 4 Is Involved in Editing of NAD4 and Affects the Splicing of NAD2 Intron 1. Plant Molecular Biology, 93, 355-368. [Google Scholar] [CrossRef] [PubMed]
[20] Rovira, A.G. and Smith, A.G. (2019) PPR Proteins—Orchestrators of Organelle RNA Metabolism. Physiologia Plantarum, 166, 451-459. [Google Scholar] [CrossRef] [PubMed]
[21] Yu, Y., Deng, H., Wang, W., Xiao, S., Zheng, R., Lv, L., et al. (2024) LRPPRC Promotes Glycolysis by Stabilising LDHA mRNA and Its Knockdown Plus Glutamine Inhibitor Induces Synthetic Lethality via m6A Modification in Triple‐negative Breast Cancer. Clinical and Translational Medicine, 14, e1583. [Google Scholar] [CrossRef] [PubMed]
[22] Hu, Y., Cui, J., Jin, L., Su, Y. and Zhang, X. (2021) LRPPRC Contributes to the Cisplatin Resistance of Lung Cancer Cells by Regulating MDR1 Expression. Oncology Reports, 45, Article No. 4. [Google Scholar] [CrossRef] [PubMed]
[23] Zhao, Z., Xu, H., Wei, Y., Sun, L. and Song, Y. (2023) Deubiquitylase PSMD14 Inhibits Autophagy to Promote Ovarian Cancer Progression via Stabilization of Lrpprc. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1869, Article ID: 166594. [Google Scholar] [CrossRef] [PubMed]
[24] Zhou, W., Wang, W., Liang, Y., Jiang, R., Qiu, F., Shao, X., et al. (2023) The RNA-Binding Protein LRPPRC Promotes Resistance to CDK4/6 Inhibition in Lung Cancer. Nature Communications, 14, Article No. 4212. [Google Scholar] [CrossRef] [PubMed]
[25] Niinuma, T., Kitajima, H., Sato, T., Ogawa, T., Ishiguro, K., Kai, M., et al. (2024) LINC02154 Promotes Cell Cycle and Mitochondrial Function in Oral Squamous Cell Carcinoma. Cancer Science, 116, 393-405. [Google Scholar] [CrossRef] [PubMed]
[26] Zeng, L., Li, Y., He, S., Xu, H., Zhang, R., Chen, K., et al. (2024) The Deubiquitinase USP44 Enhances Cisplatin Chemosensitivity through Stabilizing STUB1 to Promote LRPPRC Degradation in Neuroblastoma. Neuro-Oncology, 27, 492-507. [Google Scholar] [CrossRef] [PubMed]
[27] Li, D. and Wang, M. (2024) An LRPPRC-HAPSTR1-PSMD14 Interaction Regulates Tumor Progression in Ovarian Cancer. Aging, 16, 6773-6795. [Google Scholar] [CrossRef] [PubMed]
[28] Zou, J., Yue, F., Li, W., et al. (2014) Autophagy Inhibitor LRPPRC Suppresses Mitophagy through Interaction with Mitophagy Initiator Parkin. PLOS ONE, 9, e94903. [Google Scholar] [CrossRef] [PubMed]
[29] Yan, G., Li, H., Zhang, Y., Xia, C., Wang, M., Jia, Y., et al. (2022) Renal Insufficiency Predicts Worse Prognosis in Newly Diagnosed IgD Multiple Myeloma Patients. Frontiers in Oncology, 12, Article 1012889. [Google Scholar] [CrossRef] [PubMed]
[30] Han, F., Sheng, N., Sheng, C. and Meng, J. (2023) The Diagnostic and Prognostic Value of Haematologic Parameters in Multiple Myeloma Patients. Hematology, 28, Article ID: 2240145. [Google Scholar] [CrossRef] [PubMed]
[31] Li, J., Arsang-Jang, S., Cheng, Y., Sun, F., D’Souza, A., Dhakal, B., et al. (2024) Enhancing Prognostic Power in Multiple Myeloma Using a Plasma Cell Signature Derived from Single-Cell RNA Sequencing. Blood Cancer Journal, 14, Article No. 38. [Google Scholar] [CrossRef] [PubMed]